Schizophrenia remains a mighty challenge to psychiatry, with its causes and underlying brain mechanisms yet to be fully uncovered. Currently available treatments are neither universally effective nor without unwanted effects. These aspects, together with the high prevalence of schizophrenia, its often debilitating nature and associated family/social burden, make this mental disorder one of the most complex public health issues of our times.

The *Advances in Schizophrenia* series intends to become a key reference in this field. Our aim is to provide comprehensive and up-to-date reviews of the wide range of research studies carried out around the world with the purposes of solving the schizophrenia puzzle and providing clues to new forms of treatment and prevention for this disorder.

A special feature of the series is its truly broad scope, virtually encompassing all fields of schizophrenia research: epidemiology and risk factors; psychopathology; diagnostic boundaries; cognition; outcome and prognosis; pathophysiology; genetics; pharmacological and psychological forms of treatment and rehabilitation; community care; and stigma.

The first volume of the series is related to the 6th Symposium on the Search for the Causes of Schizophrenia, held in Sao Paulo, Brazil, in February 2009. We have been organizing the Search-Meetings since 1986. During these 22 years we have managed to keep the main characteristic of this series: the “Search” remains a non-commercial meeting, with a limited number of invited guest speakers and participants. A group of prominent scientists from different centers around the world were invited to provide scholar reviews on the state of the art in each of the above areas, as well as their view on the perspectives for the future. The content table of this book reflects the program of the 6th edition of this meeting and is consistent with our aim to comprehensively cover all relevant areas of research into schizophrenia.

Of the five previous meetings we organized with our friend Heinz Haefner, three took place in Heidelberg and the last two in Brazil. These meetings resulted in five books, edited by Heinz and one of us (WFG) and published by Springer. In this 6th Search, for personal reasons, Heinz could not participate in the preparations of the meeting and in the edition of this book. Nevertheless, we thought that this would be an excellent occasion to dedicate this 6th Search and the first volume of this *Advances in Schizophrenia* series to Heinz Haefner. We feel that Heinz Haefner...
deserves this homage as one of the most influential psychiatrists of our time, who has given important contributions to both the knowledge about schizophrenia and the care of its sufferers.

In a time of global economic crisis we are indebted to those companies that, in spite of sensitive reductions in their budgets, have given us the financial support for the meeting, which resulted in the production of this book. Therefore, in our name and if we may, in the name of all participants of the 6th Search and authors of this book, we would like to thank, indeed, the unrestricted educational grants provided by Janssen-Cilag, Eli Lilly, and Astra Zeneca.

São Paulo, November 2009

Wagner F. Gattaz
Geraldo Busatto
# Contents

## Part I  Epidemiology And Risk Factors

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence and Outcome of Schizophrenia Across the Globe</td>
<td>3</td>
</tr>
<tr>
<td>Paulo R. Menezes</td>
<td></td>
</tr>
<tr>
<td>Gene–Environment Interactions for Searchers: Collaboration</td>
<td>19</td>
</tr>
<tr>
<td>Between Epidemiology and Molecular Genetics</td>
<td></td>
</tr>
<tr>
<td>Jim van Os, Bart P.F. Rutten, and Richie Poulton</td>
<td></td>
</tr>
<tr>
<td>The Natural History of the Course and Outcome of Schizophrenia</td>
<td>51</td>
</tr>
<tr>
<td>Judith Allardyce and Jim van Os</td>
<td></td>
</tr>
<tr>
<td>Impact of Contextual Environmental Mechanisms on the Incidence</td>
<td>67</td>
</tr>
<tr>
<td>of Schizophrenia and Other Psychoses</td>
<td></td>
</tr>
<tr>
<td>James B. Kirkbride</td>
<td></td>
</tr>
</tbody>
</table>

## Part II  Pathophysiology

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disinhibition of Prefrontal Cortex Neurons in Schizophrenia</td>
<td>99</td>
</tr>
<tr>
<td>B. Moghaddam and A.L. Pehrson</td>
<td></td>
</tr>
<tr>
<td>Brain Anatomical Abnormalities in Schizophrenia:</td>
<td>113</td>
</tr>
<tr>
<td>Neurodevelopmental Origins and Patterns of Progression over Time</td>
<td></td>
</tr>
<tr>
<td>Geraldo F. Busatto, Marcus V. Zanetti, Maristela S. Schaufelberger,</td>
<td></td>
</tr>
<tr>
<td>and José A.S. Crippa</td>
<td></td>
</tr>
<tr>
<td>The Neuropathology of Schizophrenia: Central Role for the Hippocampus?</td>
<td>149</td>
</tr>
<tr>
<td>Peter Falkai, Eleni Parlapani, Oliver Gruber, and Andrea Schmitt</td>
<td></td>
</tr>
<tr>
<td>Molecular Neuroimaging, Pathophysiological Mechanisms,</td>
<td>167</td>
</tr>
<tr>
<td>and Drug Discovery</td>
<td></td>
</tr>
<tr>
<td>Philip McGuire</td>
<td></td>
</tr>
</tbody>
</table>
Part III  Genetics

Animal Models of Schizophrenia: Focus on Hippocampal Disruption of Dopamine System Regulation ............... 175
Anthony A. Grace

Genetic and Proteomic Studies in Schizophrenia ....................... 193
Emmanuel Dias-Neto, Daniel Martins-de-Souza, Elida P.B. Ojopi, and Wagner F. Gattaz

Neurogenetic Risk Mechanisms of Schizophrenia: An Imaging Genetics Approach ......................... 219
Andreas Meyer-Lindenberg

Progress in Genetic Studies of Schizophrenia ...................... 233
Renan P. Souza, Marco A. Romano Silva, and James L. Kennedy

Part IV  Psychopathology, Cognition, Outcome

Prediction of Psychosis Through the Prodromal Syndrome .... 251
Tyrone D. Cannon

Schizophrenia as a Cognitive Disorder: Recent Approaches to Identifying its Core Cognitive Components to Aid Treatment Development .............................................. 267
Keith H. Nuechterlein, Michael F. Green, and Robert S. Kern

Cognitive and Social Processes in Psychosis: Recent Developments . . . 283
Daniel Freeman

The Impact of Early Intervention in Schizophrenia .............. 299
Alison R. Yung, Eoin J. Killackey, Barnaby Nelson, and Patrick D. McGorry

The Cross-Sectional and Longitudinal Architecture of Schizophrenia: Significance for Diagnosis and Intervention? . . . . 317
Wolfgang Gaebel, Wolfgang Wölwer, Mathias Riesbeck, and Jürgen Zielasek

Part V  Schizophrenia and Other Psychotic Disorders:
Boundaries and Similarities

Continua or Classes? Vexed Questions on the Latent Structure of Schizophrenia ................................................. 333
Richard J. Linscott, Mark F. Lenzenweger, and Jim van Os

Integrating the Epidemiology and Pathogenesis of Schizophrenia from the Street to the Striatum: Integrating the Epidemiology and Pathogenesis of Schizophrenia ............... 357
Robin M. Murray, Marta Di Forti, and Oliver Howes
Contents ix

Cannabis: A Clue or a Distraction in the Search for ‘Causes’ of Psychosis? .......................... 367
John McGrath and Louisa Degenhardt

The ‘Totality’ of Psychosis: Epidemiology and Developmental Pathobiology .......................... 377

Part VI Treatment

Comparative Efficacy and Safety of First- and Second-Generation Antipsychotics in the Treatment of Schizophrenia: Facts and Fiction ........................................ 389
Rajiv Tandon, and Babu Rankapalli

Long-Acting Antipsychotic Medication and the Outcome of Schizophrenia .......................... 403
Anthony S. David, Ayana Gibbs, and Maxine X. Patel

Modern Community Care Strategies for Schizophrenia Care: Impacts on Outcome .............. 417
Tom Burns

Does Stigma Impair Treatment Response and Rehabilitation in Schizophrenia? The “Contribution” of Mental Health Professionals .................................................. 429
Wulf Rössler

Treatment of Schizophrenia: Discussion ..................................................... 441
Shôn Lewis

Index ........................................................................................................... 447
Contributors

Judith Allardyce  Department of Psychiatry and Neuropsychology, South Limburg Mental Health Research and Teaching Network, EURON, Maastricht University, PO Box 616 (DRT 10), 6200 MD Maastricht, The Netherlands, j.allardyce@clinmed.gla.ac.uk

Patrizia A. Baldwin  Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland; Cavan-Monaghan Mental Health Service, St. Davnet’s Hospital, Monaghan, Ireland

David Browne  Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland; Cavan-Monaghan Mental Health Service, St. Davnet’s Hospital, Monaghan, Ireland

Tom Burns  University of Oxford, Warneford Hospital, Oxford, OX3 7JX, UK, tom.burns@psych.ucla.edu

Geraldo F. Busatto  Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, 05403–903, São Paulo, SP, Brazil, geraldobusatto@hcnet.usp.br

Tyrone D. Cannon  Departments of Psychology and Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, California, USA, cannon@psych.ucla.edu

José A.S. Crippa  Laboratory of Psychiatric Neuroimaging (LIM21) Department and Institute of Psychiatry, Faculty of Medicine - University of São Paulo, 05403–903, São Paulo - SP - Brazil, jcrippa@fmrp.usp.br

Anthony S. David  Section of Cognitive Neuropsychiatry, Institute of Psychiatry, KCL, London SE5 8AF, UK, anthony.david@iop.kcl.ac.uk

Louisa Degenhardt  National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia, l.degenhardt@unsw.edu.au

Emmanuel Dias-Neto  Laboratory of Neuroscience, Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, 05403–903, São Paulo, SP, Brazil, emmanuel@usp.br
Peter Falkai  Department of Psychiatry and Psychotherapy, University of Goettingen, von Siebold Str. 5, 37075 Goettingen, Germany, pfalkai@gwdg.de

Daniel Freeman  Department of Psychology, Institute of Psychiatry, King’s College London, Denmark Hill, London, SE5 8AF, UK, d.freeman@iop.kcl.ac.uk

Marta Di Forti  Institute of Psychiatry, Box PO63, De Crespigny Park, London, SE5 8AF, UK, m.diforti@iop.kcl.ac.uk

Wolfgang Gaebel  Department of Psychiatry and Psychotherapy, Heinrich-Heine-University Düsseldorf, Clinics of the Rhineland Regional Council, Bergische Landstraße 2, D-40629 Düsseldorf, Germany, wolfgang.gaebel@uni-duesseldorf.de

Wagner F. Gattaz  Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, 05403–903, São Paulo, SP, Brazil, gattaz@usp.br

Ayana Gibbs  Section of Cognitive Neuropsychiatry, Institute of Psychiatry, KCL, London SE5, UK, agibbs@uci.edu

Anthony A. Grace  Departments of Neuroscience, Psychiatry and Psychology, A210 Langley Hall, University of Pittsburgh, Pittsburgh, PA 15260, USA, graceaa@pitt.edu

Michael F. Green  Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California; Mental Illness Research, Education, and Clinical Center, VISN 22, VA Greater Los Angeles Healthcare System, Los Angeles, USA, mgreen@ucla.edu

Oliver Gruber  Department of Psychiatry and Psychotherapy, University of Goettingen, von Siebold Str. 5, 37075 Goettingen, Germany, ogruber@gwdg.de

Robin J. Hennessy  Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland, rhennessy@rcsi.ie

Oliver Howes  Institute of Psychiatry, Box PO63, De Crespigny Park, London, SE5 8AF, UK, o.howes@iop.kcl.ac.uk

James L. Kennedy  Neurogenetics Section, Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada, james_kennedy@camh.net

Robert S. Kern  Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California; Mental Illness Research, Education, and Clinical Center, VISN 22, VA Greater Los Angeles Healthcare System, Los Angeles, USA, rkern@ucla.edu

Eoin J. Killackey  Orygen Youth Research Centre, University of Melbourne, Melbourne, Victoria, Australia, eoin@unimelb.edu.au

Tara Kingston  Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland; Cavan-Monaghan Mental Health Service, St. Davnet’s Hospital, Monaghan, Ireland, kingstontara@yahoo.co.uk
Anthony Kinsella  Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland

James B. Kirkbride  Department of Psychiatry, University of Cambridge, Cambridge, UK, jbk25@cam.ac.uk

Mark F. Lenzenweger  Department of Psychology, State University of New York at Binghamton; Department of Psychiatry and Personality Disorders Institute, Weill College of Medicine at Cornell University, New York, USA, mlenzen@binghamton.edu

Shôn Lewis  Professor of Adult Psychiatry and Head, Community-Based Medicine Research School University of Manchester, shon.lewis@manchester.ac.uk

Richard J. Linscott  Department of Psychology, University of Otago, Dunedin, New Zealand, linscott@psy.otago.ac.nz

Daniel Martins-de-Souza  Laboratory of Neuroscience, Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, 05403–903, São Paulo, SP, Brazil, java99@unicamp.br

Paulo R. Menezes  Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, pmenezes@usp.br

Andreas Meyer-Lindenberg  Central Institute of Mental Health, Zentralinstitut für Seelische Gesundheit, J5, 68159 Mannheim, Germany, a-meyer-lindenberg@zi-mannheim.de

Patrick D. McGorry  Orygen Youth Research Centre, University of Melbourne, Melbourne, Victoria, Australia, pmcgorry@unimelb.edu.au

John McGrath  Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Wacol, QLD 4076, Australia, john_mcgrath@qcmhr.uq.edu.au

Philip McGuire  Section of Neuroimaging, Institute of Psychiatry, OASIS, SLAM NHS Trust, London, p.mcguire@iop.kcl.ac.uk

B. Moghaddam  Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA, USA, moghaddam@bns.pitt.edu

Robin M. Murray  Institute of Psychiatry, Box PO63, de Crespigny Park, London SE5 8AF, UK, robin.murray@iop.kcl.ac.uk

Barnaby Nelson  Orygen Youth Research Centre, University of Melbourne, Melbourne, Victoria, Australia, nelsonb@unimelb.edu.au

Keith H. Nuechterlein  Department of Psychiatry and, Biobehavioral, Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, USA, keithn@ucla.edu

Eadbhard O’Callaghan  DETECT Early Psychosis Service, Co. Dublin, Ireland, eadbhard@gmail.com
Elida P.B. Ojopi  Laboratory of Neuroscience, Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, 05403–903, São Paulo, SP, Brazil, elida@usp.br

Olabisi Owoeye  Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland; Cavan-Monaghan Mental Health Service, St. Davnet’s Hospital, Monaghan, Ireland

Eleni Parlapani  Department of Psychiatry and Psychotherapy, University of Goettingen, von Siebold Str. 5, 37075 Goettingen, Germany

Maxine X. Patel  Section of Cognitive Neuropsychiatry, Institute of Psychiatry, KCL, London SE5 8AF, UK, m.patel@iop.kcl.ac.uk

A.L. Pehrson  Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA, USA, pehrson@pitt.edu

Richie Poulton  Dunedin Multidisciplinary Health and Development Research Unit, Department of Preventive and Social Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand, richie.poulton@otago.ac.nz

Babu Rankapalli  Clinical Assistant Professor of Psychiatry, University of Florida Medical School, Gainesville, Florida, USA, akbabu_2001@yahoo.com

Mathias Riesbeck  Department of Psychiatry and Psychotherapy, Heinrich-Heine-University, Düsseldorf, Germany

Marco A. Romano Silva  Laboratorio de Neurociencias, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil, romano-silva@ufmg.br

Wulf Rössler  Department of General and Social Psychiatry, Psychiatric University Hospital Zurich, Militärstrasse 8, 8021 Zürich, Switzerland, roessler@dgsp.uzh.ch

Vincent Russell  Cavan-Monaghan Mental Health Service, Cavan General Hospital, Cavan, Ireland; Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland

Bart P.F. Rutten  Department of Psychiatry and Neuropsychology, School of Mental Health and Neuroscience, Maastricht University Medical Centre, EURON, SEARCH, Maastricht, 6200 MD, The Netherlands

Maristela S. Schaufelberger  Laboratory of Psychiatric Neuroimaging (LIM21) Department and Institute of Psychiatry, Faculty of Medicine - University of São Paulo, 05403–903, São Paulo - SP - Brazil, maristela_ss@yahoo.com.br

Andrea Schmitt  Department of Psychiatry and Psychotherapy, University of Goettingen, von Siebold Str. 5, 37075 Goettingen, Germany, aschmit@gwdg.de

Paul J. Scully  Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland; Cavan-Monaghan Mental Health Service, St. Davnet’s Hospital, Monaghan, Ireland
Contributors

**Renan P. Souza**  Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, ON, Canada, renandesouza@camh.net

**Rajiv Tandon**  University of Florida Medical School, Gainesville, Florida, USA, tandon@ufl.edu

**Jim Van Os**  Department of Psychiatry and Neuropsychology, School of Mental Health and Neuroscience, Maastricht University Medical Centre, EURON, SEARCH, Maastricht, 6200 MD, The Netherlands; Division of Psychological Medicine, Institute of Psychiatry, London SE5 8AF, UK, j.vanos@sp.unimaas.nl

**John L. Waddington**  Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland; Cavan-Monaghan Mental Health Service, St. Davnet’s Hospital, Monaghan, Ireland, jwadding@rcsi.ie

**Wolfgang Wölwer**  Department of Psychiatry and Psychotherapy, Heinrich-Heine-University, Düsseldorf, Germany, woelwer@uni-duesseldorf.de

**Alison R. Yung**  Orygen Youth Research Centre, University of Melbourne, Melbourne, Victoria, Australia, ryung@unimelb.edu.au

**Marcus V. Zanetti**  Laboratory of Psychiatric Neuroimaging (LIM21) Department and Institute of Psychiatry, Faculty of Medicine - University of São Paulo, 05403–903, São Paulo - SP - Brazil, marcus_zanetti@yahoo.com.br

**Jürgen Zielasek**  Department of Psychiatry and Psychotherapy, Heinrich-Heine-University, Düsseldorf, Germany, juergen.zielasek@lvr.de